40 citations
,
January 2003 in “Gynecological Endocrinology” This study found that finasteride significantly reduced hirsutism in women with idiopathic hirsutism or polycystic ovary syndrome over six months, suggesting its potential effectiveness for this condition.
34 citations
,
January 2004 in “Revista do Hospital das Clínicas” The authors reported that young men with infertility-related conditions experienced improved seminal quality after stopping finasteride, suggesting potential adverse effects on fertility during treatment.
26 citations
,
June 2010 in “Acta Pharmaceutica” The researchers reported that they successfully developed and validated RP-HPLC and TLC methods for accurately measuring tamsulosin hydrochloride and finasteride in combination forms.
20 citations
,
April 2012 in “Fertility and Sterility” In this laboratory study with rats, treatment with finasteride reduced dihydrotestosterone levels and fertility parameters, with a 30-day recovery period proving insufficient to fully restore sperm function and fertility.
14 citations
,
January 2003 in “Actas Urológicas Españolas” This review found strong evidence supporting Finasteride's effectiveness in reducing symptoms and improving quality of life in patients with larger prostate volumes, earning it a grade A recommendation for clinical use.
13 citations
,
February 2015 in “Journal of Pharmaceutical Sciences” This study found that the polymorphic forms I, II, and III of finasteride can be prepared purely, with form III being identical to what was previously referred to as form X.
11 citations
,
January 2018 in “Asian Journal of Andrology” Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.
5 citations
,
June 2008 in “Acta Cirurgica Brasileira” This study found that finasteride administration in hamsters led to significant spermatogenesis reduction and seminiferous tubule atrophy compared to the control group.
1 citations
,
October 2023 in “Journal of personalized medicine” In this study, researchers investigated genetic variants in pharmacogenes affecting tadalafil and finasteride pharmacokinetics, finding fed volunteers had higher drug exposure than fasting individuals, but genetic variation did not significantly impact pharmacokinetics after correcting for multiple comparisons.
1 citations
,
January 2021 in “Acta Cirurgica Brasileira” This study found that both finasteride and dutasteride led to morphological and functional kidney damage in rats, with more severe effects observed in the dutasteride group.
August 2021 in “Research, Society and Development” In this study, intradermal therapy with Minoxidil, growth factors, and vitamins showed a slight advantage in increasing hair volume over a combination with Finasteride for androgenic alopecia.
January 2017 in “Revista da Universidade Vale do Rio Verde” This review discusses the use of finasteride for treating androgenic alopecia in men and examines its potential impacts on health, such as anxiety, libido, and fertility, without presenting new clinical results.
January 2017 in “Más dermatología” This article discusses finasteride as a treatment for alopecia, noting previous presentations at scientific forums, and reports no new findings.
August 2026 in “Asclepius International Journal of Scientific Health Science” In this systematic review, dutasteride may be more effective than finasteride for hair growth in men with androgenetic alopecia, but the comparative magnitude of this effect is highly uncertain.
May 2026 in “RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218” This study reviewed recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, detailing its association with sexual dysfunction, mood disorders, insulin resistance, and other metabolic disorders, suggesting persistent biopsycho-social risks beyond transient side effects in users.
January 2026 in “Revista Colombiana de Ciencias Químico Farmacéuticas” This review discusses the efficacy of Minoxidil and finasteride for treating androgenetic alopecia and suggests that combined therapy may offer superior results and improved patient adherence despite potential side effects.
January 2026 in “Magazine Portal Bibliotech Digital (Universidad Nacional de Colombia)” This study reviewed the literature on Minoxidil and finasteride for androgenetic alopecia, finding both drugs effective but noting potential side effects, with combined therapy possibly enhancing efficacy and patient adherence while reducing adverse effects.
This study reviews existing literature on regenerative therapy for androgenetic alopecia, highlighting that integrating growth factors, biotin, D-pantenol, and other active ingredients using the Vittahair protocol may enhance hair follicle regeneration, increase hair density, and improve hair quality, providing a precise and evidence-based treatment alternative.
February 2025 in “Ciencia Latina Revista Científica Multidisciplinar” This in-silico study found that Finasteride interferes with neurotransmitters and may increase psychopathology when it decomposes into a carboxylic acid similar to Cortisol.
October 2024 in “Actas Dermo-Sifiliográficas” Finasteride and dutasteride can increase beard thickness in men.
July 2024 in “Actas Dermo-Sifiliográficas” Finasteride and dutasteride do not significantly change beard thickness in men.
May 2024 in “Brazilian Journal of Hair Health” This study reported the successful development of finasteride-loaded poly(lactic-co-glycolic acid) nanoparticles, with varying encapsulation efficiencies, aiming to enhance drug delivery for hair growth while minimizing side effects, and noted that an in vivo study will follow to assess efficacy.
March 2023 in “Enciclopédia Biosfera” The researchers reported that finasteride was effective in controlling hormone-related dysfunction in an adult dog diagnosed with benign prostatic hyperplasia, although the condition regressed after the medication was withdrawn.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” In this integrative literature review, the researchers reported that finasteride appears highly effective for treating androgenetic alopecia and acne, showing notable benefits after brief treatment durations, though careful dose management is required due to potential sexual side effects.
May 2020 in “riUfes (Universidade Federal do Espírito Santo)” This study found that finasteride is stable under various stress conditions except for basic hydrolysis at extreme pH levels and identified compatible and incompatible excipients in pharmaceutical formulations, suggesting formulation changes for increased safety.
This study observed that intrauterine and early postnatal exposure to finasteride affected prostatic development in Mongolian gerbils, with significant sex-based differences, particularly higher alterations in female prostates.
This dissertation found that finasteride reduced prostate volume by 6.3% and total serum PSA by 10.51% in young patients over one year.
January 2016 in “Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)” This study aims to develop three topical formulations of finasteride to reduce its side effects for treating androgenic alopecia.
October 2015 in “Digital Library of Theses and Dissertations (Universidade de São Paulo)” This study observed smaller reductions in PSA levels in men under 40 taking finasteride 1mg/day compared to older age groups, without changes in testosterone levels.
February 2013 in “Americanae (AECID Library)” In this study, finasteride exposure in human prostatic cell lines did not affect cell proliferation but significantly reduced MMP activity and increased TIMP expression, potentially inhibiting tumor cell invasion and metastasis.